GlassScriptPhysician profile
Donna S Benford
NPI 1073670154
$6,114.57
in general payments reported to CMS, 2019-2025
39 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $485 · 2021: $1,077 · 2022: $912 · 2023: $1,033 · 2024: $1,097 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.02 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $876.71 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $691.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $559.30 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $363.84 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $305.61 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $255.85 | 2019-2025 | Veozah, Myrbetriq |
| Neurocrine Biosciences, INC. | $217.15 | 2019-2025 | Ingrezza |
| Exact Sciences Corporation | $211.50 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $173.68 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $128.20 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $114.75 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $111.08 | 2021-2025 | Rexulti |
| Dexcom, INC. | $105.78 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $100.86 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Benford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.